Schering is preparing a mid-2006 US launch of the hormone replacement therapy Angeliq following the FDA's approval of the therapy today. Analysts said the German drug company should garner about €250 million per year from the product. Jointly owned by Schering and Berlex Laboratories, Angeliq is already available in Europe.
- read this story from AFX for more information